Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDMNASDAQ:HSDTNASDAQ:NDRANASDAQ:TIVC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDMAradigm$0.24$0.07▼$2.33$761K1.5797,091 shsN/AHSDTHelius Medical Technologies$4.28+2.8%$5.01$3.32▼$24.60$1.75M1.1189,058 shs12,825 shsNDRAENDRA Life Sciences$3.23+0.6%$4.23$2.90▼$602.00$1.82M0.19140,443 shs62,355 shsTIVCTivic Health Systems$4.27-1.2%$4.15$2.43▼$16.08$2.62M2.03646,994 shs28,142 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDMAradigm0.00%0.00%0.00%0.00%0.00%HSDTHelius Medical Technologies-3.48%-3.26%-8.17%-49.30%-82.34%NDRAENDRA Life Sciences+2.56%-47.80%+1.58%-35.99%-99.99%TIVCTivic Health Systems0.00%+4.22%+13.09%-55.50%-49.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDMAradigmN/AN/AN/AN/AN/AN/AN/AN/AHSDTHelius Medical Technologies0.9366 of 5 stars0.05.00.00.02.80.80.0NDRAENDRA Life Sciences1.9051 of 5 stars3.52.00.00.01.60.01.3TIVCTivic Health Systems0.1058 of 5 stars0.02.00.00.01.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDMAradigm 0.00N/AN/AN/AHSDTHelius Medical Technologies 2.00HoldN/AN/ANDRAENDRA Life Sciences 3.00Buy$50.001,447.99% UpsideTIVCTivic Health Systems 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ARDM, TIVC, NDRA, and HSDT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025NDRAENDRA Life SciencesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $50.00(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDMAradigm$14.47M0.00N/AN/A($0.83) per share0.00HSDTHelius Medical Technologies$434K4.03N/AN/A$3.32 per share1.29NDRAENDRA Life SciencesN/AN/AN/AN/A$1,170.18 per shareN/ATIVCTivic Health Systems$780K3.36N/AN/A$2.44 per share1.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDMAradigm-$10.70M-$0.72N/AN/AN/A-374.80%N/A-374.15%N/AHSDTHelius Medical Technologies-$8.85M-$47.53N/A∞N/A-1,764.74%-244.82%-127.10%N/ANDRAENDRA Life Sciences-$10.06M-$624.72N/AN/AN/AN/A-127.39%-103.77%N/ATIVCTivic Health Systems-$8.24MN/A0.00∞N/A-670.95%-201.30%-154.54%N/ALatest ARDM, TIVC, NDRA, and HSDT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025TIVCTivic Health SystemsN/A-$2.52N/A-$2.52N/A$0.07 million5/1/2025Q1 2025HSDTHelius Medical Technologies-$0.58-$0.51+$0.07-$0.51N/A$0.05 million3/31/2025Q4 2024NDRAENDRA Life Sciences-$4.10-$9.40-$5.30-$20.78N/AN/A3/25/2025Q4 2024HSDTHelius Medical Technologies-$14.10-$15.45-$1.35-$1.03$0.10 million$0.15 million3/21/2025Q4 2024TIVCTivic Health Systems-$85.00-$19.68+$65.32N/A$1.43 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDMAradigmN/AN/AN/AN/AN/AHSDTHelius Medical TechnologiesN/AN/AN/AN/AN/ANDRAENDRA Life SciencesN/AN/AN/AN/AN/ATIVCTivic Health SystemsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDMAradigmN/A1.231.23HSDTHelius Medical TechnologiesN/A3.613.10NDRAENDRA Life SciencesN/A6.106.10TIVCTivic Health SystemsN/A5.654.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDMAradigm30.04%HSDTHelius Medical Technologies18.63%NDRAENDRA Life Sciences1.19%TIVCTivic Health Systems4.25%Insider OwnershipCompanyInsider OwnershipARDMAradigm4.50%HSDTHelius Medical Technologies17.90%NDRAENDRA Life Sciences0.04%TIVCTivic Health Systems0.31%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDMAradigmN/A15.22 millionN/AOptionableHSDTHelius Medical Technologies30409,0003.54 millionNot OptionableNDRAENDRA Life Sciences20562,000537,000Not OptionableTIVCTivic Health Systems10613,0009.44 millionNot OptionableARDM, TIVC, NDRA, and HSDT HeadlinesRecent News About These CompaniesTivic Health’s Strategic Shift: Earnings Call InsightsMay 16 at 8:47 PM | tipranks.comTivic Health signals strategic transformation with $8.4M financing and biopharma focus amid market repositioningMay 16 at 5:34 AM | msn.comTivic Health Systems Inc. (TIVC) Q1 2025 Earnings Call TranscriptMay 15 at 10:13 PM | seekingalpha.comTivic Reports First Quarter 2025 Financial Results and Provides Updates on Business TransformationMay 15 at 4:19 PM | businesswire.comTivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA SubmissionMay 14 at 12:00 PM | finance.yahoo.comTivic adds new vagus nerve stim patentMay 13 at 4:19 PM | massdevice.comTivic Expands VNS Intellectual Property PortfolioMay 13 at 8:30 AM | businesswire.comTivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and WebcastMay 9, 2025 | businesswire.comTivic Health reports White House briefings, FDA meetings on product applicationsApril 23, 2025 | markets.businessinsider.comTivic Health Systems Stock Is On Fire Today: What's Going On?April 22, 2025 | benzinga.comTivic Health Systems Shares Rise on White House and FDA BriefingsApril 22, 2025 | marketwatch.comTivic Health Stock Doubles After Briefings To Senior Leadership At White House, FDA: But Retail Stays BearishApril 22, 2025 | msn.comTivic Health shares soar on defense application interestApril 22, 2025 | investing.comTivic Health exercises licensing option for EntolimodApril 17, 2025 | markets.businessinsider.comTivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of NeutropeniaApril 15, 2025 | businesswire.comTivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing RuleApril 10, 2025 | businesswire.comTivic Health Systems, Inc. (NASDAQ:TIVC) Q4 2024 Earnings Call TranscriptMarch 26, 2025 | msn.comTivic Health Systems’ Earnings Call Highlights Strategic ShiftMarch 24, 2025 | tipranks.comTivic Health Reports 2024 Results and Strategic GrowthMarch 22, 2025 | tipranks.comTivic Health targets FDA approval for Entolimod within 18 months, highlights transformation into biopharmaMarch 21, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARDM, TIVC, NDRA, and HSDT Company DescriptionsAradigm NASDAQ:ARDMAradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. The company is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis, and has tested for the prevention and treatment of inhaled bioterrorism infections, such as Coxiella burnetii or Q fever, inhalation anthrax, tularemia, melioidosis and pneumonic plague. Aradigm Corporation has collaboration agreements with Grifols, S.A. The company was founded in 1991 and is headquartered in Hayward, California.Helius Medical Technologies NASDAQ:HSDT$4.28 +0.12 (+2.76%) Closing price 03:55 PM EasternExtended Trading$4.22 -0.05 (-1.26%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.ENDRA Life Sciences NASDAQ:NDRA$3.23 +0.02 (+0.62%) Closing price 04:00 PM EasternExtended Trading$3.35 +0.12 (+3.68%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.Tivic Health Systems NASDAQ:TIVC$4.27 -0.05 (-1.16%) Closing price 04:00 PM EasternExtended Trading$4.10 -0.17 (-3.98%) As of 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades An Acquisition Just Made Dick's the Most Exciting Stock in Retail CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
